KTRA Kintara Therapeutics Inc: Earnings per share for the last 12 months

Kintara (KTRA) - corporate logo

High demand for brain tumor medications creates excellent sales prospects for Kintara Therapeutics (KTRA). The YoY ttm change in net income per share allows for a real-time assessment of capital freeze risks, and 24.50 shows the level of this metric. Business resilience is limited by a lack of recurring revenue and a dependence on grants, while global conflicts complicate patent protection and component logistics.

Kintara (KTRA) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/18/2026

KTRA (Kintara Therapeutics Inc): analytical breakdowns and indicator data

- company stock capitalization data:
Fundamental company valuation:KTRA Kintara
Flagship merchandise of Kintara Therapeutics, Inc.

This indicator reflects the rolling annual trend of net earnings per share, measuring the efficiency of business capitalization amid interest rate volatility. For Kintara Therapeutics (KTRA), this metric is critical due to costly oncology research and liquidity shortage risks. By analyzing the EPS growth rate over the last 12 months YoY, an investor can discern the company's actual resilience to operating losses. A negative trend here signals a threat to the issuer's survival.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months Inhibrx Corp (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Earnings per share for the last twelve months|NVCT - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months coherus.com|CRBP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Cardiff Oncology, Inc. CRDF|Net earnings per share for the last 12 months BYSI|Net earnings per one share for the last twelve months BioAtla BCAB|Net earnings per share for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Earnings per share for the trailing year|Cellectar Biosciences - Net earnings per share for the last 12 months|Earnings per share for the last four quarters BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year APRE (aprea.com)|KZIA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Silexion (SLXN)|Earnings per share for the last twelve months nucana.com|CMRX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) CYCC|Net earnings per share (EPS TTM) G1 Therapeutics Inc. (GTHX)|Earnings per share for the last twelve months Kronos Bio Corp KRON|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months